Welcome to our dedicated page for Achilles Therapeutics Plc news (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics Plc stock.
Achilles Therapeutics Plc (ACHL) delivers precision T-cell therapies targeting clonal neoantigens in solid tumors through its AI-driven PELEUS platform. This news hub provides investors and researchers with authoritative updates on the company’s clinical milestones, scientific advancements, and strategic initiatives.
Access real-time announcements including clinical trial results, regulatory filings, and research collaborations. Our curated collection ensures you stay informed about developments in NSCLC and melanoma trials, technology enhancements to the PELEUS bioinformatics system, and partnership announcements shaping the future of personalized cancer immunotherapy.
Bookmark this page for streamlined access to Achilles Therapeutics’ verified press releases and analysis-driven news coverage. Check regularly for updates reflecting the company’s progress in advancing patient-specific immunotherapies through rigorous clinical validation and operational execution.
Achilles Therapeutics (NASDAQ: ACHL) announced on April 21, 2023, that it received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement for its American Depositary Shares (ADS). The company has until October 18, 2023, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Despite this notice, Achilles' ADSs will continue to trade on the Nasdaq Global Select Market. The company is actively monitoring its bid price and may consider options to regain compliance. Achilles is developing AI-powered precision T cell therapies for cancer treatments and has ongoing Phase I/IIa trials for patients with advanced non-small cell lung cancer and metastatic melanoma.
Achilles Therapeutics has announced the granting of US patent 11,634,773, which focuses on immunotherapy targeting neoantigens linked to specific HLA alleles preserved in tumors. This patent enables treatment via various modalities such as vaccines and T cell therapies. The proprietary sequence-based method allows identification of HLA loss, crucial for developing effective cancer treatments. This technology is integrated into the company's PELEUS™ bioinformatics platform, facilitating personalized treatment strategies in clinical trials. Achilles, a clinical-stage biopharmaceutical company, is actively working on T cell therapies targeting clonal neoantigens in ongoing trials for advanced non-small cell lung cancer and metastatic melanoma.
FAQ
What is the current stock price of Achilles Therapeutics Plc (ACHL)?
What is the market cap of Achilles Therapeutics Plc (ACHL)?
